Validation of the eighth clinical American Joint Committee on Cancer stage grouping for esophageal cancer.
AIM
To validate the American Joint Committee on Cancer (AJCC) clinical staging system for esophageal cancer using Surveillance, Epidemiology and End Results database.


METHODS
Cancer-specific survival analyses for clinically-staged patients with esophageal cancer according to both seventh and eighth editions were conducted through Kaplan-Meier analysis.


RESULTS
For cancer-specific survival according to both seventh and eighth clinical systems, p-values for pairwise comparisons were nonsignificant in many comparisons. C-index for adenocarcinoma was: 0.671 according to the seventh AJCC and 0.671 according to the clinical eighth AJCC. C-index for squamous cell carcinoma according to the seventh AJCC was: 0.634 and 0.643 according to clinical eighth AJCC.


CONCLUSION
Minimal improvement was achieved by the eighth clinical AJCC staging system for esophageal cancer.
['Oweira|Hani|H|', 'Schmidt|Jan|J|', 'Mehrabi|Arianeb|A|', 'Kulaksiz|Hasan|H|', 'Schneider|Paul|P|', 'Schöb|Othmar|O|', 'Giryes|Anwar|A|', 'Abdel-Rahman|Omar|O|']
D000230:Adenocarcinoma D000328:Adult D000368:Aged D002294:Carcinoma, Squamous Cell D018572:Disease-Free Survival D004938:Esophageal Neoplasms D005260:Female D006801:Humans D053208:Kaplan-Meier Estimate D008297:Male D008875:Middle Aged D009367:Neoplasm Staging D011379:Prognosis D018426:SEER Program D014481:United States
staging esophageal cancer SEER prognosis